IP Library › Granted Patent US 12,269,155
Granted Patent B2
US 12,269,155 · App. 17/307,066 · Granted Apr 8, 2025

Multivalent vaccines for rabies virus and coronaviruses

Inventors: Reed F. Johnson (Frederick, MD); Matthias Schnell (Harleysville, PA); Lisa E. Hensley (Frederick, MD); Christoph Wirblich (Philadelphia, PA); Christopher M. Coleman (Owings Mills, MD); Matthew S. Frieman (Baltimore, MD)
Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; Thomas Jefferson University; University of Maryland, Baltimore
B25H3/003A61K39/12A61K39/205A61K39/215C12N15/86A61K2039/5254A61K2039/5256C12N2760/20034C12N2760/20043C12N2760/20134C12N2760/20143C12N2770/20022C12N2770/20034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,155
App. No.
17/307,066
Granted
Apr 8, 2025
Kind
B2
Abstract

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

Claims (24)

1. A recombinant rabies virus vector comprising a nucleotide sequence encoding at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-CoV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).

2. The recombinant rabies virus vector of claim 1 , wherein the truncation includes at least one selected from the group consisting of (a) the deletion of from about 15 to about 35 amino acids from the c-terminus (b) and the deletion of about 19 amino acids from the C-terminus.

3. The recombinant rabies virus vector of claim 1 , wherein the immunogenic glycoprotein fragment includes the S1 domain of a spike protein.

4. The recombinant rabies virus vector of claim 1 , wherein the immunogenic glycoprotein fragment is a chimeric protein including the immunogenic glycoprotein fragment and a membrane anchor from a virus other than a coronavirus.

5. The recombinant rabies virus vector of claim 4 , wherein the membrane anchor is from a RABV glycoprotein.

6. The recombinant rabies virus vector of claim 5 , wherein the membrane anchor includes at least a portion of at least one of the ectodomain, the transmembrane domain, the cytoplasmic domain of the RABV glycoprotein, or a combination thereof.

7. The recombinant rabies virus vector of claim 1 , wherein an amino acid sequence of the at least one immunogenic glycoprotein fragment is selected from the group consisting of SEQ ID NO: 8, 12, or 14.

8. The recombinant rabies virus vector of claim 1 , wherein the rabies virus genome is attenuated.

9. The recombinant rabies virus vector of claim 1 , wherein the rabies virus vector is derived from the live attenuated SAD B19 RABV vaccine.

10. A host cell comprising the recombinant rabies virus vector of claim 1 .

11. An isolated virion prepared from a host cell infected with the recombinant rabies virus vector of claim 1 .

12. A multivalent vaccine effective to induce an immune response against both rabies and at least one coronavirus, comprising the recombinant rabies virus vector of claim 1 .

13. The multivalent vaccine according to claim 12 , wherein the rabies virus genome further expresses one or more additional coronavirus protein or immunogenic fragment thereof.

14. The multivalent vaccine according to claim 13 , wherein the additional coronavirus protein is selected from the group consisting of a replicase polyprotein, E protein, N protein, M protein, or nonstructural proteins from MERS-COV or SARS-COV.

15. A vaccine composition comprising one or more multivalent vaccine of claim 12 and a pharmaceutically acceptable carrier.

16. The vaccine composition according to claim 15 , further comprising at least one additional therapeutic agent.

17. The vaccine composition according to claim 16 , wherein the therapeutic agent is at least one of an anti-viral drug, an anti-viral antibody, an immunostimulatory agent, an adjuvant, or a combination thereof.

18. A method of inducing an immune response against a coronavirus or a rabies virus, or both, in a subject, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine comprising a recombinant rabies virus vector of claim 1 .

19. A method of inducing neutralizing antibodies against coronavirus or a rabies virus, or both, in a subject infected with or having been exposed to either or both of said viruses, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine of claim 12 .

20. A method of treating a subject infected with a coronavirus or a rabies virus, or both, comprising administering to the subject a therapeutically effective amount of a multivalent vaccine of claim 12 , wherein said vaccine induces an effective immune response against one or both of said viruses.

21. A live, replication-competent, rabies virus based vector expressing at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-COV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).

22. The vector according to claim 21 , wherein the vector has the nucleotide sequence of SEQ ID NO: 21, 23, or 24.

23. A live, replication-deficient, rabies virus based vector expressing at least one immunogenic glycoprotein fragment comprising a C-terminal truncation of a spike protein of Middle East Respiratory Coronavirus (MERS-COV) or Severe Acute Respiratory Syndrome Coronavirus (SARS-COV).

24. The vector according to claim 23 , wherein the vector has the nucleotide sequence of SEQ ID NO: 21, 23, or 24.

Continuity (3)
Continuation 16091005
Provisional Application 62318087 · Apr 4, 2016
Related Publication 20220072697A1 · Mar 10, 2022
References Cited (71)
US 11041170B2 · Johnson · 2021 [cited by examiner]
US 11478543B1 · Schnell · 2022 [cited by examiner]
US 20110064764A1 · Faber · 2011 [cited by applicant]
WO 02089728A2 · 2002 [cited by applicant]
WO 2002089728 · 2002 [cited by applicant]
WO 2012106490A1 · 2012 [cited by applicant]
WO 2014055289A1 · 2014 [cited by applicant]
Schwegmann-Wessels C, Ren X, Herrler G. 2006. Intracellular transport of the S proteins of coronaviruses. Adv Exp Med Biol 581:271-275. [cited by applicant]
Siler C A, McGettigan J P, Dietzschold B, Herrine S K, Dubuisson J, Pomerantz R J, Schnell M J. 2002. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292:24-34. [cited by applicant]
Smith M E, Koser M, Xiao S, Siler C, McGettigan J P, Calkins C, Pomerantz R J, Dietzschold B, Schnell M J. 2006. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353:344-356. [cited by applicant]
Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G. 2015. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Synd… [cited by applicant]
Wang L, Shi W, Joyce M G, Modjarrad K, Zhang Y, Leung K, Lees C R, Zhou T, Yassine H M, Kanekiyo M, Yang Z Y, Chen X, Becker M M, Freeman M, Vogel L, Johnson J C, Olinger G, Todd J P, Bagci U, Solomon J, Mollura D J, He… [cited by applicant]
WHO. 2015. Rabies, Fact Sheet #99. 5 pages. [cited by applicant]
Willet M, Kurup D, Papaneri A, Wirblich C, Hooper J W, Kwilas S A, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney J E, Johnson R F, Schnell M J. 2015. Preclinical Devel… [cited by applicant]
Winter C, Schwegmann-Wessels C, Neumann U, Herrler G. 2008. The spike protein of infectious bronchitis virus is retained intracellularly by a tyrosine motif. J Virol 82:2765-2771. [cited by applicant]
Wirblich Christoph et al, “One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus”, BIOSIS, Biosciences Information Service, Philadel… [cited by applicant]
Yang Y, Deng Y, Wen B, Wang H, Meng X, Lan J, Gao G F, Tan W. 2014. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents… [cited by applicant]
Zaki A M, van Boheemen S, Bestebroer T M, Osterhaus A D, Fouchier R A. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. [cited by applicant]
Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng C T, Zhou Y, Perlman S, Jiang S, Du L. 2015. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccine… [cited by applicant]
Zhao J, Li K, Wohlford-Lenane C, Agnihothram S S, Fett C, Gale M J, Jr., Baric R S, Enjuanes L, Gallagher T, McCray P B, Jr., Perlman S. 2014. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc… [cited by applicant]
Zhu X, Liu Q, Du L, Lu L, Jiang S. 2013. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis 5 Suppl 2:S142-148. [cited by applicant]
Anna H. Malczyk et al, “A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform Abstract”, Journal of Virology., US, (Sep. 9, 2015),… [cited by applicant]
Anonymous. 2013. WHO Statement on the third meeting of the IHR Emergency committee concerning Middle East respiratory syndrome coronavirus (MERS-CoV). Wkly Epidemiol Rec 88:435-436. [cited by applicant]
Azhar E I, El-Kafrawy S A, Farraj S A, Hassan A M, Al-Saeed M S, Hashem A M, Madani T A. 2014. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370:2499-2505. [cited by applicant]
Blaney J E, Marzi A, Willet M, Papaneri A B, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell M J. 2013. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunize… [cited by applicant]
Blaney J E, Wirblich C, Papaneri A B, Johnson R F, Myers C J, Juelich T L, Holbrook M R, Freiberg A N, Bernbaum J G, Jahrling P B, Paragas J, Schnell M J. 2011. Inactivated or live-attenuated bivalent vaccines that conf… [cited by applicant]
Cauchemez S, Van Kerkhove M D, Riley S, Donnelly C A, Fraser C, Ferguson N M. 2013. Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. Euro Surveill 18. 13 pag… [cited by applicant]
Chan PK, Ma S, Ngai S M. 2011. Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods. Hong Kong Med J 17 Suppl 6:26-30. [cited by applicant]
Cliquet F, Aubert M. 2004. Elimination of terrestrial rabies in Western European countries. Dev Biol (Basel) 119:185-204. abstract. [cited by applicant]
Coleman C M, Frieman M B. 2015. Growth and Quantification of MERS-CoV Infection. Current protocols in microbiology 37:15E 12 11-19. [cited by applicant]
Coleman C M, Liu Y V, Mu H, Taylor J K, Massare M, Flyer D C, Glenn G M, Smith G E, Frieman M B. 2014. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32:3169… [cited by applicant]
Coleman C M, Matthews K L, Goicochea L, Frieman M B. 2013. Wild type and innate immune deficient mice are not susceptible to the Middle East Respiratory Syndrome Coronavirus. J Gen Virol doi: 10.1099/vir.0.060640-0. 5 p… [cited by applicant]
Conzelmann K K, Cox J H, Schneider L G, Thiel H J. 1990. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175:485-499. [cited by applicant]
Drosten C, Kellam P, Memish Z A. 2014. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 371:1359-1360. [cited by applicant]
Du L, Jiang S. 2015. Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther 15:1647-1651. [cited by applicant]
Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath A K, Zheng B J, Zhou Y, Jiang S. 2013. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory… [cited by applicant]
Foley et al. PNAS, 2000, vol. 97 (26), pp. 14680-14685. [cited by applicant]
Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, Itamura S, Kurane I, Morikawa S. 2005. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen V… [cited by applicant]
Guo X, Deng Y, Chen H, Lan J, Wang W, Zou X, Hung T, Lu Z, Tan W. 2015. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike… [cited by applicant]
Hudacek A W, Al-Saleem F H, Willet M, Eisemann T, Mattis J A, Simpson L L, Schnell M J. 2014. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol… [cited by applicant]
Huttner A, Dayer J A, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves A R, Hooper J W, Kaya G, Krahling V, Kwilas S, Lemaitre B, Matthey A, Silvera P, Becker S, Fast P E, Moorthy V, Kieny… [cited by applicant]
International Preliminary Report on Patentability for App. No. PCT/US2017/025623, dated Oct. 9, 2018, 13 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/2017/025623, dated Aug. 8, 2018. [cited by applicant]
J. P. McGettigan et al., “Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic”, Journal of Virology, (Jan… [cited by applicant]
Kawase et al. Journal of Virology, 2019, vol. 93, Issue 19, pp. 00785-19. [cited by applicant]
Khan A, Farooqui A, Guan Y, Kelvin D J. 2015. Lessons to learn from MERS-CoV outbreak in South Korea. J Infect Dev Ctries 9:543-546. [cited by applicant]
Kim E, Okada K, Kenniston T, Raj V S, AlHajri M M, Farag E A, AlHajri F, Osterhaus A D, Haagmans B L, Gambotto A. 2014 Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c… [cited by applicant]
Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell M J. 2014. Rhabdoviral-Based Vaccine Platforms against Henipaviruses. J Virol doi:10.1128/JVI.0.2308-14. 11 pages. [cited by applicant]
Lontok E, Corse E, Machamer C E. 2004. Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site. J Virol 78:5913-5922. [cited by applicant]
M. Faber: “A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome ronavirus (SARS-CoV)S protein results in the production of high levels of SARS-CoV-neutralizing antibodies”, … [cited by applicant]
Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng C T, Zhou Y, Du L, Jiang S. 2014. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses t… [cited by applicant]
Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng C T, Li F, Zhou Y, Jiang S, Du L. 2014. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—the importance of immunofocusing i… [cited by applicant]
Madani T A, Azhar E I, Hashem A M. 2014. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 371:1360. [cited by applicant]
McGettigan J P, Naper K, Orenstein J, Koser M, McKenna P M, Schnell M J. 2003. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine ve… [cited by applicant]
McKenna P M, Pomerantz R J, Dietzschold B, McGettigan J P, Schnell M J. 2003. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizin… [cited by applicant]
Memish Z A, Zumla A I, Assiri A. 2013. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 369:884-886. [cited by applicant]
Milne-Price S, Miazgowicz K L, Munster VJ. 2014. The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis 71:121-136. [cited by applicant]
Mou H, Raj V S, van Kuppeveld F J, Rottier P J, Haagmans B L, Bosch B J. 2013. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that e… [cited by applicant]
Munster, Pneumonia from Human Coronavirus in a Macaque Model. N Engl J Med, 2012, 368.1560-1562. http://www.nejm.org/doi/abs/10.1056/NEJMc1215691. [cited by applicant]
Muthumani K, Falzarano D, Reuschel E L, Tingey C, Flingai S, Villarreal D O, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga A M, Soule G, Morrow M, Kraynyak K A, Khan A S, Scott D P, Feldmann F, LaCasse R, Meade-White K,… [cited by applicant]
Papaneri A B, Wirblich C, Cann JA, Cooper K, Jahrling P B, Schnell M J, Blaney J E. 2012. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virolog… [cited by applicant]
Papaneri A B, Wirblich C, Cooper K, Jahrling P B, Schnell M J, Blaney J E. 2012. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vacci… [cited by applicant]
Papaneri A B, Wirblich C, Marissen W E, Schnell M J. 2013. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment. Vaccine 31:5897-59… [cited by applicant]
Park H Y, Lee E J, Ryu Y W, Kim Y, Kim H, Lee H, Yi S J. 2015. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to Jun. 2015. Euro Surveill 20:1-6. [cited by applicant]
Pascal K E, Coleman C M, Mujica A O, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk J M, Matthews KL, Babb R, Chen G, Lai KM, Huang T T, Olson W, Yancopoulos G D, Stahl N, Frieman M B, Kyratsous C A.… [cited by applicant]
Petersen E, Pollack M M, Madoff L C. 2014. Health-care associate transmission of Middle East Respiratory Syndrome Corona virus, MERS-CoV, in the Kingdom of Saudi Arabia. Int J Infect Dis 29:299-300. [cited by applicant]
Pfaller C K, Cattaneo R, Schnell M J. 2015. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (60 year edition), accepted. 34 pages. [cited by applicant]
Roper R L, Rehm K E. 2009. SARS vaccines: where are we? Expert Rev Vaccines 8:887-898. [cited by applicant]
Schnell M J, Foley H D, Siler C A, McGettigan J P, Dietzschold B, Pomerantz R J. 2000. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97:3544-3549. [cited by applicant]
Schwegmann-Wessels C, Al-Falah M, Escors D, Wang Z, Zimmer G, Deng H, Enjuanes L, Naim H Y, Herrler G. 2004. A novel sorting signal for intracellular localization is present in the S protein of a porcine coronavirus but… [cited by applicant]
Schwegmann-Wessels C, Glende J, Ren X, Qu X, Deng H, Enjuanes L, Herrler G. 2009. Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. J Gen Virol 90:1724-1729. [cited by applicant]